| [1] |
YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64( 1): 73- 84. DOI: 10.1002/hep.28431.
|
| [2] |
BYRNE CD, TARGHER G. Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications[J]. Diabetes Obes Metab, 2022, 24( Suppl 2): 28- 43. DOI: 10.1111/dom.14484.
|
| [3] |
MUSSO G, GAMBINO R, TABIBIAN JH, et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: A systematic review and meta-analysis[J]. PLoS Med, 2014, 11( 7): e1001680. DOI: 10.1371/journal.pmed.1001680.
|
| [4] |
MANTOVANI A, PETRACCA G, BEATRICE G, et al. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: A meta-analysis of observational cohort studies[J]. Gut, 2022, 71( 4): 778- 788. DOI: 10.1136/gutjnl-2021-324191.
|
| [5] |
LI F, LI MW, WANG YS. Therapeutic paradigms and potential therapies for nonalcoholic steatohepatitis[J]. J Clin Hepatol, 2024, 40( 10): 2082- 2086. DOI: 10.12449/JCH241025.
李凤, 李茂微, 王雨杉. 非酒精性脂肪肝病的治疗模式和潜在疗法[J]. 临床肝胆病杂志, 2024, 40( 10): 2082- 2086. DOI: 10.12449/JCH241025.
|
| [6] |
LI L, LIU DW, YAN HY, et al. Obesity is an independent risk factor for non-alcoholic fatty liver disease: Evidence from a meta-analysis of 21 cohort studies[J]. Obes Rev, 2016, 17( 6): 510- 519. DOI: 10.1111/obr.12407.
|
| [7] |
VACHLIOTIS I, GOULAS A, PAPAIOANNIDOU P, et al. Nonalcoholic fatty liver disease: Lifestyle and quality of life[J]. Hormones(Athens), 2022, 21( 1): 41- 49. DOI: 10.1007/s42000-021-00339-6.
|
| [8] |
MARJOT T, MOOLLA A, COBBOLD JF, et al. Nonalcoholic fatty liver disease in adults: Current concepts in etiology, outcomes, and management[J]. Endocr Rev, 2020, 41( 1): bnz009. DOI: 10.1210/endrev/bnz009.
|
| [9] |
ZHU F, WANG LM, JI CP, et al. Relationship between the C-reactive protein and nonalcoholic fatty liver disease prevalence[J]. Clin Med China, 2015, 31( 9): 812- 816. DOI: 10.3760/cma.j.issn.1008- 6315.2015.09.013.
朱峰, 王来明, 季春鹏, 等. 血清C反应蛋白与非酒精性脂肪性肝病的相关性研究[J]. 中国综合临床, 2015, 31( 9): 812- 816. DOI: 10.3760/cma.j.issn.1008- 6315.2015.09.013.
|
| [10] |
ZHU F, WANG LM, JI CP, et al. Predictive value of C-reactive protein in emerging non-alcoholic fatty liver disease[J]. Chin J Hepatol, 2016, 24( 8): 575- 579. DOI: 10.3760/cma.j.issn.1007-3418. 2016.08.004.
朱峰, 王来明, 季春鹏, 等. C-反应蛋白对新发非酒精性脂肪肝的预测价值[J]. 中华肝脏病杂志, 2016, 24( 8): 575- 579. DOI: 10.3760/cma.j.issn.1007-3418.2016.08.004.
|
| [11] |
CHEN CX, DU J, SONG J, et al. Study on correlation between serum hypersensitive C-reactive protein and nonalcoholic fatty liver disease in the elderly[J]. Chin J Gen Prac, 2023, 21( 9): 1491- 1494. DOI: 10.16766/j.cnki.issn.1674-4152.003153.
陈长喜, 杜娟, 宋健, 等. 血清超敏C反应蛋白与老年人非酒精性脂肪肝的相关性[J]. 中华全科医学, 2023, 21( 9): 1491- 1494. DOI: 10.16766/j.cnki.issn.1674-4152.003153.
|
| [12] |
LING Q, CHEN JW, LIU X, et al. The triglyceride and glucose index and risk of nonalcoholic fatty liver disease: A dose-response meta-analysis[J]. Front Endocrinol(Lausanne), 2023, 13: 1043169. DOI: 10.3389/fendo.2022.1043169.
|
| [13] |
National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association, Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34( 5): 947- 957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.
中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34( 5): 947- 957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.
|
| [14] |
ZHENG RJ, DU ZN, WANG MM, et al. A longitudinal epidemiological study on the triglyceride and glucose index and the incident nonalcoholic fatty liver disease[J]. Lipids Health Dis, 2018, 17( 1): 262. DOI: 10.1186/s12944-018-0913-3.
|
| [15] |
KIM KS, HONG SM, AHN HY, et al. Triglyceride and glucose index is a simple and easy-to-calculate marker associated with nonalcoholic fatty liver disease[J]. Obesity(Silver Spring), 2022, 30( 6): 1279- 1288. DOI: 10.1002/oby.23438.
|
| [16] |
LEE J, YOON K, RYU S, et al. High-normal levels of hs-CRP predict the development of non-alcoholic fatty liver in healthy men[J]. PLoS One, 2017, 12( 2): e0172666. DOI: 10.1371/journal.pone.0172666.
|
| [17] |
ZHANG YX, WANG Y, YOU CL, et al. Analysis of related factors of abnormal liver function in patients with nonalcoholic fatty liver disease[J]. Clin J Med Offic, 2025, 53( 5): 522- 524,528. DOI: 10.16680/j.1671-3826.2025.05.21.
张月霞, 王宇, 尤丛蕾, 等. 非酒精性脂肪肝患者肝功能异常相关因素分析[J]. 临床军医杂志, 2025, 53( 5): 522- 524, 528. DOI: 10.16680/j.1671-3826.2025.05.21.
|
| [18] |
LEE JW, CHO YK, RYAN M, et al. Serum uric Acid as a predictor for the development of nonalcoholic fatty liver disease in apparently healthy subjects: A 5-year retrospective cohort study[J]. Gut Liver, 2010, 4( 3): 378- 383. DOI: 10.5009/gnl.2010.4.3.378.
|
| [19] |
KIDA Y, SATO T. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease[J]. Ann Intern Med, 2006, 144( 5): 379- 380; author reply 380. DOI: 10.7326/0003-4819-144-5-200603070-00022.
|
| [20] |
MIN YY, ZHANG P, TIAN PR, et al. The mechanism of bariatric surgery in the treatment of non-alcoholic fatty liver disease[J]. Chin J Dig Surg, 2024, 23( 9): 1231- 1236. DOI: 10.3760/cma.j.cn115610-20240614-00296.
闵逸洋, 张鹏, 田沛荣, 等. 减重手术治疗非酒精性脂肪性肝病的作用机制[J]. 中华消化外科杂志, 2024, 23( 9): 1231- 1236. DOI: 10.3760/cma.j.cn115610-20240614-00296.
|
| [21] |
GRANDER C, GRABHERR F, TILG H. Non-alcoholic fatty liver disease: Pathophysiological concepts and treatment options[J]. Cardiovasc Res, 2023, 119( 9): 1787- 1798. DOI: 10.1093/cvr/cvad095.
|